¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ ÃֽŠ[ÀÓ»óÀÇÇÐ] ¿¬±¸µ¿Çâ Å°¿öµå ³×Æ®¿öÅ© ºÐ¼®
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 

 

ÃֽŠÀÇ°úÇÐ Å°¿öµå ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®

 

[ÀÓ»óÀÇÇÐ] ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®





 

7¿ù¿¡ ÀÇ°úÇÐºÐ¾ß ±¹³»¿Ü Àú³ÎÀ» ÅëÇØ ¹ßÇ¥ÇÑ ÀÓ»óÀÇÇÐ ³í¹®Àº 1,839ÆíÀÌ ¹ßÇ¥µÇ¾ú´Ù. ÀÌ´Â Àü¿ù ¹ßÇ¥µÈ ÀÓ»óÀÇÇÐ ³í¹®Æí¼ö¿¡ ºñÇÏ¿© 16.3%ÀÎ 259ÆíÀÌ Áõ°¡µÇ¾ú´Ù. ÀÌ °¡¿îµ¥ ±¹³» Àú³ÎÀ» ÅëÇÑ ¹ßÇ¥´Â 977Æí°ú, ±¹¿Ü Àú³ÎÀ» ÅëÇÏ¿© 862ÆíÀÌ ¹ßÇ¥µÇ¾î ±¹³» Àú³ÎÀ» ÅëÇÑ ¹ßÇ¥°¡ 11.8% ¿ìÀ§¸¦ Â÷ÁöÇÏ¿´´Ù. 




 

 

                        ±×¸² 1.  ÀÓ»óÀÇÇÐ7¿ù ÇÙ½É Å°¿öµå ¿¬±¸µ¿Çâ Ŭ¶ó¿ìµå




 

 

                  ±×¸² 2. ±¹³» 7¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®




 

 

                        ±×¸² 3. ±¹¿Ü 7¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ ³×Æ®¿öÅ© ºÐ¼®



 

Ç¥  1.  ÀÓ»óÀÇÇÐ 7¿ù ÅäÇÈ ³×Æ®¿öÅ© ¸ðµ¨¸µ   

Topic1

Topic2

Topic3

Topic4

Topic5

Anxiety

Genes

Neoplasms

Pain

Risk

Older Adults

Role

Survival Rate

General Surgery

Bmi

Adult

Humans

General Surgery

Exercise

Mortality

COVID-19

Serum

Recurrence

F-18 Fdg Pet

Diabetes

Women

Liver

Sensitivity And Specificity

Brain

Drug

Pediatrics

Economics

Breast Neoplasms

Ankle

Women

Adolescent

Inflammation

Risk

Learning

Stroke

Depression

Biological Markers

Women

Complication

Hypertension

Behavior

Fibrosis

Neoplasm Metastasis

Wounds And Injuries

Sex

Vaccination

Culture

Drug Therapy

Disability

Risk Factors

 




 

 

                    

                     ±×¸² 4.  ÀÓ»óÀÇÇÐ ÅäÇÈ Å°¿öµå ³×Æ®¿öÅ© ¿¬±¸µ¿Ç⠺м® 





 

Ç¥  2.   7¿ù ÀÓ»óÀÇÇÐ ¿¬±¸µ¿Çâ »óÀ§ Å°¿öµå (n=1,839)

 

Å°¿öµå ¼øÀ§

±¹³» ÀÓ»óÀÇÇÐ Å°¿öµå

±¹¿Ü ÀÓ»óÀÇÇÐ Å°¿öµå

ÅëÇÕ ÀÓ»óÀÇÇÐ Å°¿öµå 

1

Risk

Risk

Risk

2

COVID-19

General Surgery

General Surgery

3

Women

Neoplasms

Women

4

General Surgery

Women

Neoplasms

5

Neoplasms

Mortality

COVID-19

6

Pain

Survival Rate

Mortality

7

Drug

Complication

Survival Rate

8

Pediatrics

Adult

Pain

9

Mortality

COVID-19

Complication

10

Complication

F-18 Fdg Pet

Adult







 

7¿ù¿¡ ¹ßÇ¥µÈ ±¹³»¿Ü ÀÇ°úÇÐºÐ¾ß ³í¹® ¹ßÇ¥ Áß¿¡¼­ ÀÓ»óÀÇÇÐ³í¹®ÀÌ Â÷ÁöÇÏ´Â ºñÀ²Àº 50.2%¸¦ Â÷ÁöÇÏ¿© Àü¿ù 49.1%¿¡ ºñ±³ÇÏ¿© ¾à°£ »ó½ÂÇÏ¿´°í ÀÇ°úÇÐ Àüü ºÐ¾ß Áß¿¡¼­ ÀÓ»óÀÇÇÐÀÌ Â÷ÁöÇÏ´Â ºñÀ²Àº Áö¼ÓÀûÀ¸·Î °¡Àå ³ôÀº ¼øÀ§¸¦ ³ªÅ¸³»¾ú´Ù.  ÃֽŠÀÓ»óÀÇÇÐ ¿¬±¸µ¿Ç⠺м®¿¡ »ç¿ëµÈ ³í¹® µ¥ÀÌÅÍ´Â ±¹³» Àú³Î°ú ÇØ¿Ü Àú³ÎÀ» ÅëÇØ  ¹ßÇ¥µÈ ³í¹® Áß¿¡¼­ Çѱ¹ÀÇÇÐ³í¹®µ¥ÀÌÅͺ£À̽º(KMbase)¿Í ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ Æà¸Þµå(PubMed) MEDLINE µ¥ÀÌÅͺ£À̽º¿¡¼­ ³í¹®ÀڷḦ ÃßÃâÇÏ¿© ºÐ¼®ÇÏ¿´´Ù. 









 

      ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Á¦°ø





 

* º» ³»¿ëÀº MedRIC (www.medric.or.kr)ÀÇ ¿¬±¸µ¿Çâ¿¡¼­ Á¦°øµÇ´Â ³»¿ëÀÔ´Ï´Ù.




 


2022-08-22 ¿ÀÈÄ 12:16:26, Á¶È¸¼ö : 494